Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA.
All News
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).
Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.
Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.
